Oxford Immunotec (OXFD) Tops Q3 EPS by 15c, Raises Revenue Outlook
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Oxford Immunotec (NASDAQ: OXFD) reported Q3 EPS of ($0.18), $0.15 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $26.1 million versus the consensus estimate of $24.79 million.
Oxford Immunotec sees FY2016 revenue of $85-85.8 million, versus prior guidance of $82.5-84.5 million and the consensus of $83.7 million.
For earnings history and earnings-related data on Oxford Immunotec (OXFD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vera Bradley (VRA) Tops Q3 EPS by 1c; Offers Light Q4 Outlook; Enters New Licensing Agreements
- SunPower (SPWR) to Commence Restructuring; Sees Charges; Offers FY17 Outlook
- Coupa Software (COUP) Tops Q3 EPS Views; Issues Confident Q4 Outlook
Create E-mail Alert Related CategoriesEarnings, Guidance
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!